It had posted standalone profit of Rs 25.71 crore for the October-December quarter of 2012-13, Wyeth said in a filing to the BSE.
Total income of the company in Q3, 2013-14 decreased to Rs 161.32 crore, from Rs 170.94 crore in the year-ago period.
Also Read
Meanwhile, Wyeth said that it has approved the scheme of amalgamation of the company with Pfizer on November 23 with a share swap ratio of seven equity shares valuing Rs 10 of Pfizer with every 10 equity shares of similar value of Wyeth.
"The company is in the process of filing the scheme with the High Court of Bombay... Pending all statutory approvals, no effect of the above scheme has been given in results," Wyeth said.
Wyeth Ltd scrip closed at Rs 709, down 2.99%, on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%